Company Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
The company’s development product portfolio includes Casdatifan, a HIF-2α inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer.
In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer.
It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer.
Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | Mar 15, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 601 |
| CEO | Terry Rosen |
Contact Details
Address: 3928 Point Eden Way Hayward, California 94545 United States | |
| Phone | 510 694 6200 |
| Website | arcusbio.com |
Stock Details
| Ticker Symbol | RCUS |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001724521 |
| CUSIP Number | 03969F109 |
| ISIN Number | US03969F1093 |
| Employer ID | 47-3898435 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Terry J. Rosen Ph.D. | Co-Founder, Chairman and Chief Executive Officer |
| Dr. Juan Carlos Jaen Ph.D. | Co- Founder and President |
| Robert C. Goeltz II | Principal Financial Officer and Chief Financial Officer |
| Jennifer A. Jarrett M.B.A. | Advisor |
| Dr. Richard A. Markus M.D., Ph.D. | Chief Medical Officer |
| Dr. K. Christopher Garcia Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Alexander Azoy CPA | Chief Accounting Officer |
| Dr. Jonathan Yingling Ph.D. | Chief Scientific Officer |
| Pia Eaves | Vice President of Investor Relations and Strategy |
| Carolyn C. Tang J.D. | General Counsel and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 12, 2026 | 8-K | Current Report |
| Jun 1, 2026 | 144 | Filing |
| May 11, 2026 | 144 | Filing |
| May 6, 2026 | 144 | Filing |
| May 5, 2026 | 10-Q | Quarterly Report |
| May 5, 2026 | 8-K | Current Report |
| Apr 23, 2026 | 144 | Filing |
| Apr 21, 2026 | ARS | Filing |
| Apr 21, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 21, 2026 | DEF 14A | Other definitive proxy statements |